PHAXIAM Therapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Equivalents	38.79	33.7	44.45	73.17	134.37	185.53	37.65	45.63
Cash & Cash Equivalents	38.79	33.7	44.45	73.17	134.37	185.53	37.65	45.63
Cash Growth	15.10%	-24.18%	-39.26%	-45.54%	-27.57%	392.81%	-17.50%	-
Receivables	0.08	0.01	0	0.04	0.03	0.08	0.22	0.42
Inventory	0	0	0	0.36	1.4	0.18	0.15	0.17
Other Current Assets	3.77	6.34	5.18	8.02	14.11	5.79	4.52	5.71
Total Current Assets	42.63	40.05	49.63	81.58	149.91	191.57	42.53	51.93
Property, Plant & Equipment	2.98	25.83	29.09	35.64	15.27	3.41	2.25	0.92
Goodwill and Intangibles	0.01	0.02	0.59	0.6	1.61	0.05	0.06	0.06
Other Long-Term Assets	0.2	0.88	1.09	0.72	1.05	0.23	0.13	0.1
Total Long-Term Assets	3.18	26.72	30.77	36.96	17.93	3.69	2.43	1.08
Total Assets	45.81	66.77	80.4	118.55	167.84	195.26	44.97	53
Accounts Payable	5.12	14.15	20.91	13.78	16.66	8.08	4.83	3.67
Current Debt	3.34	1.98	3.87	1.52	0.78	0.82	0.05	0.56
Other Current Liabilities	3.22	3.87	4.57	4.58	3.22	2.71	1.47	1.39
Total Current Liabilities	11.68	20.01	29.35	19.88	20.65	11.61	6.35	5.62
Long-Term Debt	10.23	23.39	23.58	12.6	1.24	2.02	2.82	0.15
Other Long-Term Liabilities	0.42	0.52	0.94	0.51	0.35	0.22	0.17	0.1
Total Long-Term Liabilities	10.65	23.92	24.52	13.11	1.59	2.24	2.98	0.25
Total Liabilities	22.32	43.92	53.86	32.99	22.24	13.84	9.33	5.87
Total Debt	13.57	25.38	27.45	14.12	2.02	2.84	2.87	0.71
Debt Growth	-46.53%	-7.55%	94.35%	599.50%	-28.98%	-0.80%	304.80%	-
Retained Earnings	-0.23	-53.8	-73.3	-62.66	-38.22	-33.53	-21.91	-15.01
Comprehensive Income	1.4	1.22	1.74	1.34	-0.19	-0.2	-0.17	0
Shareholders' Equity	23.49	22.85	26.54	85.56	145.6	181.42	35.64	47.13
Net Cash / Debt	25.22	8.32	17	59.05	132.35	182.68	34.78	44.93
Net Cash / Debt Growth	203.00%	-51.03%	-71.21%	-55.38%	-27.55%	425.25%	-22.58%	-
Working Capital	30.96	20.04	20.29	61.7	129.26	179.96	36.19	46.31
Book Value Per Share	7.57	8.64	14.79	47.69	81.17	106.32	20.89	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).